Nycomed is a privately owned, global pharmaceutical company with headquarters in Zurich, Switzerland. The company employs 12,000 associates worldwide and has affiliates in more than 50 countries. 

Nycomed has a strong presence in Europe and in the emerging markets in Russia/Commonwealth of Independent States, Asia and Latin America.

Business results and main therapeutic areas

In 2009, total sales reached € 3.2 billion, with an adjusted EBITDA of € 1.1 billion. Nycomed ranks 28th among global pharmaceutical companies and is the 16th largest provider of OTC medicines.

Nycomed’s differentiated portfolio of branded medicines is focused on gastroenterology, respiratory and inflammatory diseases, pain, osteoporosis and tissue management. An extensive range of OTC products completes the portfolio.

Global R&D and Manufacturing presence

Research and Development is conducted at three sites in Europe and one in India. New products are sourced from our own internal Discovery organisation and in-licensed from external companies such as small biotechs. Establishing long-term partnerships is a cornerstone of Nycomed´s growth strategy. 

Nycomed has 16 manufacturing sites: 5 centres of competence in Europe for global products as well as 11 production sites for regional products in fast-growing countries such as Brazil and Mexico. A major investment is being made in a new pharmaceutical plant in Russia, currently Nycomed’s biggest single market.